• (+30) 210 650 2542
  • (+30) 6974 465 626
  • fanis_fl@yahoo.gr
logo
  • Αρχική
  • Βιογραφικό
  • Υπηρεσίες
  • Αρθρογραφία
  • Βίντεο
  • Τα νέα μας
  • Επικοινωνία
  • Αρχική
  • Βιογραφικό
  • Υπηρεσίες
  • Αρθρογραφία
  • Βίντεο
  • Τα νέα μας
  • Επικοινωνία

Αρθρογραφία

  • Home
  •  
  • Αρθρογραφία
    • 23 Σεπτεμβρίου 2022

    1975P – Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers

    T. Floros, E. Papadopoulou, V. Metaxa-Mariatou, A. TsantikidiZ, G. Kapetsis, C. Florou-Chatzigiannidou, A. Meintani, N. Touroutoglou, I. Boukovinas4, F. Stavridi, C. Papadimitriou, D. Ziogas, M. Theochari, E. Timotheadou, A. Fassas, Z. Saridaki-Zoras, M. Ozdogan, U. Demirci, G. Nasioulas INTRODUCTION The use of PARP inhibitors has been shown to be beneficial in tumors with BRCA1/2 mutations

    Read more
    • 7 Μαΐου 2022

    Πρώτη χορήγηση TRASTUZUMAB DERUXTECAN (ENHERTU®) σε Έλληνες ασθενείς με γαστρεντερικό καρκίνο: Αποτελεσματικότητα και ασφάλεια

    Μπαξεβάνος Π., Φλώρος Θ., 6ο Ελληνικό Συνέδριο Ογκολογίας Εισαγωγή To Enhertu® είναι ένα συζευγμένο φάρμακο τηςτραστουζουμάμπης (μονοκλωνικό αντίσωμα έναντι του υποδοχέα HER2) με 8 μόρια δερουξτεκάνης (αναστολέας τοποίσο με ράσ η ς I). Έχει λάβει ένδειξη από ΕΜΑ για τη θεραπεία ασθενών με ανεγχείρητο ΗΕ82-θετικό καρκίνο μαστού, και πρόοδο νόσου σε 2 τουλάχιστον στοχευτικές αντι-ΗΕΚ2

    Read more
    • 25 Οκτωβρίου 2021

    Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients

    GEORGIOS N. TSAOUSIS, EIRINI PAPADOPOULOU, KONSTANTINOS AGIANNITOPOULOS, GEORGIA PEPE, NIKOLAOS TSOULOS, IOANNIS BOUKOVINAS, THEOFANIS FLOROS, RODONIKI IOSIFIDOU, OURANIA KATOPODI, ANNA KOUMARIANOU, CHRISTOS MARKOPOULOS, KONSTANTINOS PAPAZISIS, VASILEIOS VENIZELOS, ACHILLEAS KAPSIMALIS, GRIGORIOS XEPAPADAKIS, AMANDA PSYRRI, EUGENIU BANU, DAN TUDOR ENIU, ALEXANDRU BLIDARU, DANA LUCIA STANCULEANU, ANDREI UNGUREANU, VAHIT OZMEN, SUALP TANSAN, MEHMET TEKINEL, SUAYIB YALCIN and GEORGE

    Read more
    • 7 Φεβρουαρίου 2019

    Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations

    Tsoulos N, Tsaousis GN, Papadopoulou E, Agiannitopoulos K, Pepe G, Kambouri S, Apessos A, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Xanthakis I, Xepapadakis G, Banu E, Eniu DT, Negru S, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G. Analysis

    Read more
    • 1 Δεκεμβρίου 2017

    Tumor molecular profiling of NSCLC patients using next generation sequencing

    Nikolaos Tsoulos, Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, Georgios Tsaousis, Chrisoula Efstathiadou, Georgia Tounta, Aikaterini Scapeti, Eugenia Bourkoula, Pavlos Zarogoulidis, George Pentheroudakis, Stylianos Kakolyris, Ioannis Boukovinas, Pavlos Papakotoulas, Elias Athanasiadis, Theofanis Floros, Anna Koumarianou, Vasileios Barbounis, Anca Dinischiotu, George Nasioulas, “Tumor molecular profiling of NSCLC patients using next generation sequencing”, Oncology Rep. 2017 Dec; 38(6):3419-3429. https://doi.org/10.3892/or.2017.6051 Abstract

    Read more
    • 1 Αυγούστου 2017

    A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

    A. Tarhini, Ahmad & Floros, Theofanis & Lin, Hui-Min & Lin, Yan & Rahman, Zahra & Ashraf, Madeeha & Vallabhaneni, Priyanka & Sander, Cindy & N.M. Rao, Uma & Panelli, Monica & LaFramboise, William & Kirkwood, John. August 2017, DOI: 10.1097/CMR.0000000000000383 Abstract The purpose of this study was to learn whether molecular characterization through gene expression

    Read more
    • 4 Μαΐου 2017

    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer

    Ahmad A. Tarhini MD, PhD, Imran Rafique MDDS, Theofanis Floros MD, Phu Tran MD, William E. Gooding MS, Liza C. Villaruz MD, Timothy F. Burns MD, PhD, David M. Friedland MD, Daniel P. Petro MD, Mariya Farooqui PhD, Jose Gomez-Garcia PhD, Autumn Gaither-Davis BS, MPH, Sanja Dacic MD, PhD, Athanassios Argiris MD, Mark A Socinski MD, Laura P. Stabile PhD, Jill M. Siegfried PhD First published: 4 May

    Read more
    • 1 Οκτωβρίου 2016

    Multidisciplinary Management of Gastrointestinal Cancers

    ISBN: 978-981-4651-87-5 This invaluable book provides an introduction to the development and application of molecular biology with a focus on translational research development in a variety of gastrointestinal cancers. Multidisciplinary Management of Gastrointestinal Cancers will emphasize the multidisciplinary aspects of GI cancer diagnosis, treatment and management, introduce the application of new techniques in GI cancer

    Read more
    • 17 Μαρτίου 2016

    A tumor and immune related miRNA signature predicts progression-free survival of melanoma patients treated with ipilimumab

    Ahmad Tarhini, Priyanka Vallabhaneni, Theofanis Floros, William A. LaFramboise, Panayiotis V. Benos and Lucas Santana dos Santos. DOI: 10.1158/1538-7445.AM2016-473 Published July 2016 Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA   Abstract Background Patients with regionally advanced melanoma were treated with neoadjuvant ipilimumab in a previously reported study (Tarhini et al, PLOS One 2014). MicroRNA (miRNA) expression profiles of tumors of treated patients were investigated for

    Read more
    • 1 Αυγούστου 2015

    Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

    Seminars in Oncology Volume 42, Issue 4, August 2015, Pages 539-548 Theofanis Floros, Ahmad A. Tarhini DOI: http://dx.doi.org/10.1053/j.seminoncol.2015.05.015 Abstract Efforts over nearly four decades have focused on ways to use cytokines to manipulate the host immune response towards cancer cell recognition and eradication. Significant advances were achieved with interleukin-2 (IL-2) and interferon-α (IFN-α), primarily in

    Read more
  • 1
  • 2
Copyright © Θεοφάνης Ειρ. Φλώρος 2021 | Σχεδίαση-Υλοποίηση yhatzis